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ENGINEERED PLATFORM TO GENERATE 3D CARDIAC TISSUES 
FOR MODELING GENETIC CARDIOMYOPATHIES 
REBECCAH J. LUU 
ABSTRACT 
Studies to gain mechanistic understanding of heart dysfunction based on animal and 
traditional cell culture models have significant limitations. Animal models are low 
throughput and fail to recapitulate many aspects of human cardiac biology, and 2D culture 
models utilizing human induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs) 
are higher throughput but fail to incorporate one or more in vivo parameters, such as 3D 
architecture, electrical pacing and mechanical constraint. High throughput 3D tissue 
platforms could better recapitulate the in vivo microenvironment of cardiac tissue. Previous 
work from our group demonstrated an approach to build 3D cardiac microtissues based on 
photolithography-based fabrication of a MEMS device, but design limitations prevented 
further iterations.  In this work, we used a 3D printing approach to engineer iPSC-CM-
derived cardiac microtissues with different form factors. Microtissues generated in this 
platform increased in lifespan compared to the first-generation platform by more than 
100%. When modeling mutations associated with genetic cardiomyopathy, functional and 
structural differences were observed between tissues composed of wild-type and mutant 
iPSC-CMs. These findings suggest that this micro-device platform can be potentially used 
for both mechanistic and drug discovery studies. 
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
 
1.1 Heart Disease and Genetic Cardiomyopathies 
Cardiovascular disease is the leading cause of death in the US1. Cardiovascular 
disease can be developed, such as coronary heart disease, hypertension and arrhythmia, or 
genetic, such as genetic cardiomyopathy. Genetic cardiomyopathies are a group of genetic 
heart muscle diseases that affect proteins in cardiomyocytes, the force generating muscle 
cells of the heart. 
There are several different types of cardiomyopathies. Dilated cardiomyopathy is 
characterized by heart wall thinning and systolic dysfunction caused by mutations that 
affect various cellular components and pathways related to tissue function and structural 
organization2. Hypertrophic cardiomyopathy (HCM) is characterized by thickening of the 
heart wall tissue, fibrosis and myocyte disorganization2. It is most commonly caused by 
mutations in the β-myosin proteins in sarcomeres, the contractile units in cardiomyocytes 
3. The R403Q mutation, one of the most widely studied mutations linked to HCM, is a 
point missense mutation in the β-myosin heavy chain (MHC) that converts an arginine 
residue to glutamine4,5. It is mechanistically unclear how this mutation causes HCM’s 
clinical phenotype, which includes fibrosis and tissue disorganization, in patients, partly 
due to a lack of human models. Animal models have provided valuable insights into the 
mechanisms of this disease however there are fundamental differences between animal and 
human cardiomyocytes. For example, adult human cardiomyocytes predominately express 
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β-MHC as opposed to mouse cardiomyocytes, which predominately express α-MHC6. This 
difference in myosin isoform expression can hamper our ability to accurately study HCM 
pathogenesis.  
 
1.2 A Need for Increasing Cardiomyocyte Maturity 
Recent advances in human induced pluripotent stem cell (iPSC) technology have provided 
a good source of cardiomyocytes, leading to the development of various 2D and 3D in vitro 
models. However, newly generated iPSC-CMs maintain an immature phenotype in which 
they are smaller in size, lack of t-tubules, have underdeveloped calcium handling 
properties, and a lower β-myosin content7,8. A higher β-myosin content may be required to 
model HCM since most of the disease-causing mutations are found in β-MHC. Time in 
culture of iPSC-CMs has been shown to enhance β-myosin content and maturation, but 
they still do not fully express the adult phenotype. In one study, iPSC-CMs were cultured 
in 2D for 120 days to achieve an increase in size, sarcomere organization, and contractile 
performance9. Another study developed a method alternating between 2D and 3D culture 
over the course of one year to enhance gene expression and ion channel function10. While 
these platforms have shown an increase in iPSC-CM maturity, they still lack features that 
exist in 3D cardiac tissue, such as myofibrillar architecture, t-tubules. Thus, 2D platforms 
are unable to faithfully recapitulate the 3D microenvironment found in native heart tissue. 
 
 
3 
 
 
 
1.3 3D Platforms for Generating Cardiac Tissues 
3D culture platforms can provide better conditions for generating functionally mature 
iPSC-CM cardiac tissues. Several platforms have been developed to generate 3D cardiac 
tissues that model human heart tissue. Desroches et al. developed a high-throughput 
platform to generate 822 3D tissues per device composed of about 1200 cells per tissue, 
but their system lacks mechanical loading, resulting in poorly developed sarcomeres 11. 
Zimmerman et al. developed a technique to generate cardiac tissue in the shape of a ring 
around two posts, simulating the mechanical loading present in vivo 12. While the system 
is a successful platform recapitulating the 3D microenvironment for engineering cardiac 
tissues, each tissue construct requires over 1.5 million cardiomyocytes and an extensive 
preparation process, making it a low-throughput system. Our lab has previously developed 
a μ-tug microwell system to generate 100 3D cardiac tissues, composed of 500 cells each, 
per device 13. This high-throughput platform utilizes a low number of cells and provides 
mechanical loading as well as boundary conditions on the tissues. The system also allows 
the assessment of real time assessment of isotonic muscle contraction. The tissues are also 
thin, overcoming the diffusion limit to produce viable tissues. However, tissues generated 
in this platform experience a short lifespan and the experimental preparation process limits 
the flexibility of the extracellular matrix (ECM) composition, so it is not an ideal platform 
for long-term tissue maturation, which may be required for certain disease modeling 
applications14. 
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1.4 Significance of Electrical Stimulation for Cardiac Tissue Maturation 
In addition to culture in 3D platforms, prolonged electrical stimulation can also increase 
the maturation of iPSC-CMs. Electrical stimulation can increase cell alignment and 
structural organization, enhance Ca2+ handling, and improve the electrophysiological 
properties of cardiomyocytes15,16. A frequency ramp-up regimen of iPSC-CM tissues over 
the course of 7 days has been shown to exhibit increased electrophysiological properties, 
such as lower excitation threshold and increased conduction velocity, as well as improve 
sarcomeric organization, producing constructs that present a more adult-like phenotype16. 
Thus, it may be advantageous to develop a platform that is compatible with electrical 
stimulation equipment for prolonged stimulation of iPSC-CM tissues to improve their 
functional maturity and phenotype. 
 
1.5 Project Aim 
For my project, I aim to develop a new high throughput platform to generate 3D cardiac 
tissues with increased tissue lifespan for modeling HCM. This platform should generate a 
high yield of tissues with a lifespan of two weeks. In addition, I aim to develop an electrical 
stimulation regimen and determine whether it increases the functional maturity of tissues 
generated in the proposed platform. The platform will be used to generate tissues to model 
a HCM mutation. I will demonstrate whether tissues generated through this engineered 
platform show functional and morphological differences between tissues composed of 
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wild-type (WT) cardiomyocytes and cardiomyocytes harboring the R403Q mutation 
(403+/-). 
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CHAPTER 2: DEVELOPMENT OF A NEW 3D PLATFORM 
 
2.1 New Platform Design Conditions and Rationale 
Our lab’s existing high-throughput μtissue platform is a strong candidate for short-
term tissue experimentation but is not an option for long-term tissue maturation, which 
may be required for certain disease modeling applications and maturation protocols. A new 
platform and procedure needed to be developed to generate a high yield of cardiac tissues 
with a lifespan of two weeks. A prototype mold was designed in SolidWorks with several 
design conditions, which included two different microwell geometries, three cap 
geometries and three post heights (Fig. 1). One microwell design featured a rectangular 
base well in which the pillars are housed, with a larger cylindrical top well for cell culture 
medium. The other microwell design featured a rectangular base well that ended at the 
bottom of the caps of the posts, with a larger volume of space around the caps, and a larger 
cylindrical top well for cell culture medium. This design was created to determine if having 
more space for media exchange around the tissue was beneficial.  
The three chosen cap geometries consisted of a drafted rectangular cap and a 
spherical cap each with a 50 μm overhang, and a spherical cap whose diameter was equal 
to the width of the pillar and thus had no overhang. Rectangular caps were adapted from 
the μtug platform. Tissues in the μtug platform displayed tears on the inner interface of the 
pillars, and a thinning of the tissue at the inner corners of the caps. Thus, spherical caps 
were tested to minimize the formation and size of those inner holes in the tissue. The 
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spherical caps were postulated to promote a more even distribution of stress than the 
rectangular caps, thus decreasing concentrations of stress at specific points of the tissue 
which could compromise the tissue’s structural integrity.  
Three different post heights were tested to change the spring constant of the pillars13 
(Table 1). The posts simulate static mechanical loading on the tissue, so posts that are too 
stiff for the tissue to displace adequately predispose the system to induce increased 
afterload17.  
The spacing in the platform was designed to be compatible with microscopes in the 
lab for real time force measurements as well as with the IonOptix C-Pace EP Culture Pacer, 
a commercially available product used for electrical stimulation of cell cultures. The mold 
generates three repeats of the platform, with lines between each device to indicate where 
to cut and a “T” marking to indicate the orientation of the different design conditions. Each 
final device features a 2x6 array of the different design conditions. 
 
 1:10 PDMS Ratio 1:20 PDMS Ratio 
Total Post Height (mm) 1.1 1.2 1.5 1.1 1.2 1.5 
Spring Constant (uN/um) 8.86 6.74 3.35 3.21 2.68 1.99 
Table 1. Spring constant of the post at different total heights and material stiffnesses. 
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2.2 Materials and Methods 
2.2.1 Initial Process for Generating Engineered Cardiac Tissues 
The prototype mold was 3D printed using stereolithography by Protolabs (Fig. 1A). 
Polydimethylsiloxane (PDMS) was used to cast the final positive mold for generating 
cardiac tissues (Fig. 1B). PDMS was made at a 1:10 ratio and poured onto the negative 3D 
printed mold and cured at 60ºC for 24 hours. The PDMS mold was then removed from the 
negative mold and cut into three strips along the indicated lines, creating the final device. 
Each device was attached to a 60 mm petri dish using PDMS and cured at 60ºC for 24 
hours. The devices were UV sterilized for 15 minutes prior to seeding.  
iPSCs were differentiated using a standardized protocol18. Briefly, iPSCs were 
cultured in Rosewell Park Memorial Institute (RPMI) medium supplemented with B-27 
minus insulin (RPMI-B27-) for 8 days. At the start of differentiation, iPSCs were treated 
with CHIR99021, a glycogen synthase kinase 3 (GSK3) inhibitor, for 24 hours. 48 hours 
after GSK3 inhibition, the cells were treated with IWP4, a Wnt inhibitor, for 24 hours in 
RPMI-B27-. On the 9th day of differentiation, cell medium was changed to RPMI 
supplemented with B-27 plus insulin (RPMI-B27+). Once the iPSC-CMs started to 
spontaneously contract, they were subjected to metabolic selection for 2 days by replacing 
glucose in the cell medium with 4mM lactate. iPSC-CMs were then replated and 
maintained in culture in RPMI-B27+ until experimentation. 
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Fig. 1. (A) Schematic of the prototype negative mold. (B) Schematic of the resulting 
positive mold. (C) Schematics of the different design conditions tested. 
 
Tissues composed of iPSC-CMs and stromal cells were cultured in H1 Media, 
composed of high glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS, Sigma), 1% Gibco GlutaMAX, 1% Gibco MEM Non-
Essential Amino Acids and 1% Penicillin Streptomycin.  
To generate tissues, a thrombin solution composed of H1 media and 0.6 U thrombin 
per mg fibrinogen was added to each well and centrifuged at 3000 RPM for 1.5 minutes to 
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uniformly distribute it across the bottom of the base well. Then, a reconstitution mixture 
cells and ECM composed of 84% iPSC-CMs and 16% neonatal human cardiac fibroblasts 
(NHCF-V), H1 Media, 2.5 mg/ml fibrinogen and 12.5% v/v Matrigel were added to each 
well and the device was shaken up/down and left/right to distribute the mixture in the wells. 
The devices were placed in a 37ºC, 5% CO2 incubator for 30 minutes for fibrinogen 
polymerization and then H1 media with 10 μM Y27632 was added to each well. The final 
volume of media in each well is about 50 μl, making it prone to evaporation. Thus, 1X 
phosphate buffer solution (PBS) was added into the petri dish to mitigate media 
evaporation. 
 
2.2.2 Chemical Treatment of the Caps 
To further increase tissue lifespan and yield, a cap chemical treatment (CCT) method was 
developed to increase cell adhesion to the PDMS caps. A CCT platform was developed 
composed of rectangular wells which could be aligned with the PDMS mold so that only 
the caps of each pillar would be in the CCT platform’s rectangular well space, allowing for 
only the caps of the pillars to be chemically treated (Fig. 2). The devices were plasma 
treated for 30 seconds. The CCT platform’s wells were filled with 0.01% poly-lysine and 
the caps were treated for 2 hours and then washed with PBS. The caps were then treated 
with 0.1% glutaraldehyde for 15 minutes. Then, the devices were washed thoroughly in 
PBS and incubated in PBS in the fridge overnight. 
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2.2.3 Optical Analysis 
To quantify tissue forces, bright field images were taken at 4x on a Nikon Eclipse Ti 
microscope. The microscope is housed in a chamber with environmental control set to 37ºC 
and 5% CO2. The displacement of the pillars can be tracked using the SpotTracker plug-in 
on ImageJ. The displacement values were then run through a custom MATLAB script to 
compute twitch force14. The spring constant of the pillars was theoretically calculated13 
(Table 1). In the final platform design fabricated in 1:20 PDMS, the spring constant of the 
pillar was calculated to be k=2.677. 
 
Fig. 2. (A) Schematic of the platform for the chemical cap treatment process. (B) Top view 
of the wells. (C) Sectioned view of a single well. 
A 
B 
C 
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2.2.4 Immunofluorescence   
Tissues were fixed in 4% paraformaldehyde for 30 minutes. Tissues were permeabilized 
with 0.1% Triton X in PBS for 1 hour. Primary antibodies were added and incubated 
overnight at 4ºC. Then, tissues were washed three times with PBS and the secondary 
antibodies were added and incubated for two hours at room temperature. Tissues were 
further incubated with the secondary antibodies at 4ºC overnight. Tissues were then washed 
three times with PBS and imaged. 
 
2.3 Results and Discussion 
2.3.1 Testing of Design Conditions and Optimization of the Tissue Generation Process 
 The goal was to generate a high yield of tissues with a lifespan of two weeks in the 
new platform. Using the initial tissue generation protocol, tissue lifespan was less than one 
week and produced a very low yield (<10%) across all design conditions. Parameters such 
as ECM composition, seeding density, cell medium composition, and orientation of the 
device at different stages of the process were optimized to increase tissue lifespan and 
yield.  
 Seeding densities ranging between 25,000-75,000 cells/well were tested. The cells 
were seeded in a fibrin-based hydrogel, which has been reported to be a favorable material 
for cardiac tissue engineering applications due to its degradability and mechanical 
properties19. It was hypothesized that the rate of fibrin degradation exceeded the rate of cell 
ECM production, leading to a low tissue lifespan and yield. Combinations of fibrinogen, 
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thrombin and Matrigel concentrations were tested to determine the optimal mixture. In 
addition, aprotinin, a fibrinolysis inhibitor, was added to the culture medium to slow down 
the fibrin degradation rates. With these changes, tissue lifespan increased to over one week.  
While the formation of tissues in the devices was successful, the tissues were 
forming around the base of the pillars as opposed to around the caps, which is critical for 
proper data measurements and analysis. So, the orientation of the device during the seeding 
process was varied. Inversion of the device only during polymerization and upright 
orientation of the device during polymerization followed by inversion of the device post-
polymerization for several days were tested. Inversion of the device during only 
polymerization produced mixed results where some tissues formed in various locations 
relative to the caps. So, the initial seeding volume was adjusted. Originally, the total 
volume of the seeding mixtures exceeded the volume capacity of the base well. So, the 
seeding volume was reduced so that the mixture would fill the base well to the middle of 
the cap. With the changes in seeding volume and device orientation, the tissues compacted 
around the caps and showed an increased lifespan to 1.5 weeks in the wells featuring 
rectangular and spherical caps with the overhang but not in the wells featuring spherical 
caps with no overhang.  
We observed the formation of holes on the inner interface of the cap to the tissue. 
To improve the compaction of the tissues around the caps, the stromal cells were switched 
from NHCF-V to human mesenchymal stem cells (hMSCs). The cell mixture was adjusted 
to 90% iPSC-CMs and 10% hMSCs. With this change, the tissue lifespan increased to two 
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weeks.  
The spherical caps with no overhang produced the lowest yield of tissues with a 
lifespan of two weeks. We concluded that the cap overhang is necessary for the tissues to 
stay on the posts and thus the non-overhanging design was removed from further 
consideration. With the optimization of the tissue generation process, tissues in this 
microwell design featuring spherical caps on the posts produced the highest yield of tissues 
with a lifespan of two weeks. In the well design featuring a larger slanted space around the 
caps, the tissues tended to adhere to the slanted wall. The 3D printed mold is fabricated in 
layers and so the slanted wall is not a smooth surface, which may lead the cells to 
preferentially adhere to that rougher surface. PDMS ratio was adjusted to 1:20 to decrease 
pillar stiffness.  
 
2.3.2 Final Platform Design 
The final platform features spherical caps on posts within individual microwells 
composed of a rectangular base well and a larger top cylindrical well (Fig. 3). The 
individual microwell design allows for each well to be seeded individually so multiple 
conditions can be tested in one device, increasing the flexibility of the platform for 
experimental conditions. The individual microwells also provide increased flexibility in 
ECM composition during cell seeding, allowing for the generation of cardiac tissues in a 
fibrin-based hydrogel. The negative mold generates six final PDMS tissue platforms, each 
featuring a 2x3 array of microwells marked with a “||” to denote the top (Fig. 3A-B). Each 
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is then adhered to a 35 mm petri dish to form the final device for cardiac tissue generation 
(Fig. 4B). The spacing within the platform is compatible with the microscopes in the lab 
for optical imaging for force measurements as well as the IonOptix C-Pace EP Culture 
Pacer, providing the flexibility to electrically stimulate the tissues and develop a regimen 
to promote tissue functional maturity. 
 
 
Fig. 3. (A) 3D CAD model of the negative mold of the final platform design. (B) 3D CAD 
model of the resulting positive platform mold. (C) Drawing of the top view of a single 
device (positive). Dimensions are in mm. 
 
A 
B 
C 
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2.3.3 Final Tissue Generation Process 
The PDMS platform mold is subjected to CCT one day prior to experimentation. A 
thrombin solution is added to each base well and the device is centrifuged at 3000 RPM 
for 1.5 minutes. A reconstitution mixture of 50,000 cells/well (90% iPSC-CMs and 10% 
hMSCs) in 4 mg/ml fibrinogen, 0.4 U thrombin per mg fibrinogen, and 10% Matrigel is 
added to each base well, and the total volume fills the base well to halfway up the cap. 
Devices are shaken up/down and left/right to distribute the reconstitution mixture. Devices 
are inverted during polymerization and then kept upright for the duration of the experiment. 
Tissues are cultured in H1 media with 0.033 mg/ml aprotinin and 10 uM Y27632 for the 
first two days and then Y27632 is removed from the media for the rest of the experiment. 
We present an optimized tissue generation process for the new platform (Fig. 4). 
The thrombin solution and reconstitution mixture volume fills the base well to halfway up 
the caps, and the device is inverted during polymerization and then kept upright for the 
duration of the experiment (Fig. 4B). Over time of cultivation, the cells compact the 
hydrogel construct around the caps, and the resulting tissue spontaneously contracts as a 
unit by day 5. The addition of aprotinin from the beginning of the process increased the 
tissue lifespan by slowing down the fibrin hydrogel degradation (not shown). We also 
present a novel method to differentially treat the caps of the pillars to promote cell-substrate 
adhesion. The combination of the tissue generation process and CCT produces a tissue 
yield of about 88% at 2 weeks. Without the CCT, the tissue yield was less than 50%. 
17 
 
 
 
 
Fig. 4. (A) Schematic of a typical experimental timeline. (B) Schematic of the device cell 
seeding process. From left to right: a single device adhered to a 35 mm dish, thrombin 
solution (yellow) is added and centrifuged for uniform distribution, reconstitution mixture 
is added (red), after fibrin polymerization media (pink) is added. 
 
2.3.4 Function and Structure of Tissues in the New Platform 
 Tissues were generated in the platform using the finalized tissue generation 
protocol (Fig. 5A). Optical videos were taken of the tissues while electrically stimulated at 
1 Hz for data analysis. The analysis reveals that the tissues can follow the applied electrical 
stimulation, producing a consistent force output (Fig. 5B). Tissues start to spontaneously 
contract by Day 5 and twitch force increases over time (Fig. 5C). Immunofluorescence 
staining and imaging reveals robust aligned cardiomyocyte sarcomere formation and 
collagen deposition (Fig. 6). 
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This new platform is a high-throughput system that produces a high yield of iPSC-
CM tissues with a lifespan of two weeks. Some tissue failures are attributed to human error, 
such as pipetting error during the addition of the reconstitution mixture to the wells, 
resulting in the formation of bubbles and an incorrect seeding density. For our studies, the 
experimental timeline is two weeks; however, further studies can be conducted to 
determine the maximum tissue lifespan in this new platform.  
 
 
Fig. 5. (A) Bright field top view image of an iPSC-CM cardiac tissue suspended between 
two posts with spherical caps. (B) Force tracing of an electrically paced cardiac tissue over 
time. (C) Mean contractile force output of iPSC-CM tissues over 15 days. Tissues start to 
contract as a unit by day 5 (N≥4, p<0.05). 
A 
C B 
* 
* 
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While tissues present aligned sarcomere formation and collagen deposition, the 
alignment can be further improved. iPSC-CM tissues were generated with GFP-labeled 
fibrinogen. Fluorescent imaging shows that fibrin is still present in the tissues after two 
weeks of culture. Additional studies on optimal aprotinin concentration over the duration 
of culture may further increase structural alignment due to increased tissue compaction and 
remodeling. 
 
 
Fig. 6. Immunofluorescence images of an iPSC-CM cardiac tissue in the new platform. (A) 
Maximum projection in the z-axis of tissue stained for Z discs (α-actinin A, green). Scale 
bar 100 μm. (B) Enlarged view of sarcomeric structures. (α-actinin A, green). Scale bar 20 
A B 
C D 
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μm. (C) Maximum projection in the z-axis of tissue stained for collagen I (red). Scale bar 
100 μm. (D) 3D reconstruction of the tissue stained for α-actinin (green), collagen I (red), 
and nuclei (blue). 
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CHAPTER 3: ELECTRICAL STIMULATION OF ENGINEERED TISSUES 
 
3.1 Experimental Motivation 
While prolonged culture in a 3D platform can improve cardiomyocyte maturity, 
electrical stimulation can be utilized to further mature cardiomyocytes. iPSC-CM tissues 
subjected to a frequency ramp-up regimen over the course of 7 days have been shown to 
exhibit increased electrophysiological properties, such as lower excitation threshold and 
increased conduction velocity, as well as improved sarcomeric organization, producing 
constructs that present a more adult-like phenotype16. The new platform was designed to 
be compatible with the IonOptix C-Pace EP Culture Pacer to allow for prolonged electrical 
stimulation of the tissues. Building off previous studies, an electrical stimulation regimen 
can be developed to increase the functional maturity and phenotype of the iPSC-CM 
tissues. Stimulated and non-stimulated tissues will be compared to determine if our 
developed electrical stimulation regimen improves the functional maturity of the iPSC-CM 
tissues. 
 
3.2 Materials and Methods 
Tissues composed of iPSC-CMs and hMSCs were generated in the PDMS molds. 
Tissues were maintained in H1 media with 10 uM Y27632 and 0.033 mg/ml aprotinin for 
the first two days and then Y27632 was removed from the media for the rest of the 
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experiment. After 5 days of pre-culture, tissues were subjected to a high frequency ramp 
up stimulation regimen using the IonOptix C-Pace EP Culture Pacer (Fig. 7). The tissues 
were subjected to a field stimulation of 1 ms pulses of 2.5V/cm over the course of 7 days 
with an incremental increase of the frequency from 1 Hz to 6 Hz. Then, the tissues were 
subjected to an exercise regimen of different frequencies and voltages for 6 hours a day for 
3 days. The tissues were kept in culture for 15 days. 
 
 
Fig. 7. Schematic of the experimental timeline of the electrical stimulation regimen. 
Tissues are pre-cultured for five days and then subjected to a frequency-ramp up regimen 
from 1 Hz to 6 Hz. Then, tissues are treated with an exercise regimen for three days, 
concluding at 10 days of electrical stimulation. 
 
3.3 Results and Discussion 
 Tissues were pre-cultured for 5 days and then subjected to an electrical stimulation 
regimen (ES+) until day 15. Control tissues were maintained in standard culture without 
electrical stimulation (ES-). ES+ tissues were subjected to a ramp-up regimen in which the 
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frequency of stimulation was increased from 1 Hz to 6 Hz over 7 days (Fig. 7). After the 
ramp up regimen, contractile force of ES+ tissues were slightly higher than ES- tissues but 
not statistically significant (Fig. 8A). Then, ES+ tissues were subjected to the exercise 
regimen for 3 days. At day 15, ES+ tissues exhibited the same trend of higher contractile 
force than ES- tissues but the difference was not statistically significant (Fig. 8A). 
Isoproterenol, a β-adrenergic agonist, was added to both ES+ and ES- tissues. β-adrenergic 
stimulation affects cardiac tissue and is related to the calcium handling properties of the 
cardiomyocytes20. ES+ tissue contractile force increased by 20.7% while ES- tissue 
contractile force increased by 6.8% (Fig. 8B). While both conditions were responsive to β-
adrenergic stimulation, the response was not statistically significant. Immunofluorescence 
imaging shows robust sarcomere alignment in ES+ tissues compared to ES- tissues (Fig. 
9). 
 
 
Fig. 8. (A) Mean contractile force of stimulated tissues (ES+) after the frequency ramp-up 
regimen (day 12; N ≥4) and after 3 days of the exercise regimen (day 15, N=4) compared 
B A 
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to non-stimulated tissues (ES-). (B) Mean contractile force of ES+ and ES- tissues in 
response to isoproterenol (day 15, N=4).  
 
Fig. 9. Immunofluorescent images of (A) ES- and (B) ES+ tissue structure (α-actinin, 
green; collagen, red; DAPI, blue). ES+ tissues present robust alignment of sarcomeres. 
 Our electrical stimulation regimen can improve the functional maturity of the iPSC-
CM tissues. The response to isoproterenol stimulation suggests that Ca2+ handling of the 
ES+ tissues was improved. The tissues’ response to electrical stimulation may not have 
been statistically significant due to a small sample size. Additional studies should be 
conducted to increase the sample size and further explore the effects of this regimen. A 
prolonged study was conducted in which tissues were stimulated for an additional week, 
leading to tissue culture in the platform for 21 days with 17 days of electrical stimulation. 
At day 21, ES+ tissues presented with a decrease in contractile force. Additional studies 
should be conducted to further optimize the electrical stimulation regimen to improve the 
A B 
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functional output after two and three weeks of culture. This drop in contractile force could 
also be due to reduced plasticity of the iPSC-CMs21. Tissues could be generated from early-
stage iPSC-CMs in which they have high cell plasticity and then subjected to the 
stimulation regimen. 
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CHAPTER 4: MODELING HYPERTROPHIC CARDIOMYOPATHY IN 
ENGINEERED TISSUES 
 
4.1 Motivation and Experimental Design Rationale  
Our current mutation of interest is the R403Q point missense mutation, one of the 
most widely studied mutations linked to HCM. It is still unclear how the mutation affects 
the function of cardiac cells and tissue and leads to the resulting clinical phenotype. Many 
studies have been conducted in animal-based models, and human-based models have 
largely focused on the effects of the mutation at the cellular and subcellular level22. In this 
work, we will model the R403Q mutation in a human-based 3D tissue platform and study 
the effects of the mutation at the tissue level. Tissues composed of iPSC-CMs harboring 
the mutation will be generated and compared to WT iPSC-CM tissues to determine if there 
are functional and morphological differences.  
 
4.2 Materials and Methods 
Isogenic WT iPSCs and iPSCs harboring the R403Q mutation (403+/-) were 
obtained from Drs. Christine and Jonathan Seidman. Both cell lines were differentiated 
using the protocol described previously. Flow cytometry was run on differentiated 
populations to determine purity between cell lines. Population purity was high in both WT 
iPSC-CMs and 403+/- iPSC-CMs, with a purity of 80% and 85% respectively. 
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WT and 403+/- tissues were generated in the platform as described previously. 
Tissues were not subjected to electrical stimulation. Optical videos were taken at Day 14 
for force measurements and analysis. 
 
4.3 Results and Discussion 
 We assessed the contractile performance of WT and 403+/- tissues under several 
conditions. Under standard culture conditions, there was an increase in contractile force 
over time (Fig. 10A). At each time point, 403+/- tissues exhibited higher contractile force 
than WT tissues, and the difference in contractile force at Day 14 was statistically 
significant. Ascorbic acid (AA, 0.15 mg/ml) was added to promote collagen deposition in 
the tissues. With the addition of ascorbic acid (AA+), contractile force of both WT and 
403+/- tissues decreased over time (Fig. 10B). At each time point, WT tissues exhibited 
higher contractile force than 403+/- tissues, and the difference at Day 7 was statistically 
significant. At day 14, there is a 58.4% difference in force between WT tissues with and 
without ascorbic acid (AA-). In the 403+/- tissues, there is a 78.4% difference in force 
between AA+ and AA- tissues (Fig. 10C). Immunofluorescence staining and imaging 
showed that under the presence of ascorbic acid there was an increase in collagen 
deposition in 403+/- tissues (Fig. 11B) compared to WT tissues (Fig. 11A). 
Our studies show that 403+/- tissues produce higher contractile force than WT 
tissues under standard conditions and that 403+/- tissues produce lower contractile force 
than WT tissues in the presence of AA. Further studies should be conducted to determine 
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its cause, such as quantifying sarcomere content and sarcomere shortening. Increased 
collagen deposition can increase the stiffness of the tissue, leading to a decrease in 
contractile force output. Thickening of the heart tissue is a clinical characteristic of HCM 
and the 403+/- mutation6. Further studies should be conducted to determine why there is 
more collagen deposition in 403+/- tissues than WT tissues in the presence of ascorbic acid. 
  
 
Fig. 10. (A) Mean tissue contractile force under standard culture conditions over time (N 
≥ 5, p<0.001). (B) Mean contractile force in the presence of ascorbic acid over time (N ≥ 
A B 
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5, p<0.05). (C) Mean contractile force of WT and 403+/- tissues +/- AA at day 14 (N ≥ 9, 
p<0.001).  
 
Fig. 11. Immunofluorescent images of (A) WT and (B) 403+/- tissues stained for collagen 
I (red). (C) Mean intensity of the collagen images. 
 
  
A B 
C 
30 
 
 
 
SUMMARY 
In this work, we present a new platform that increased tissue lifespan compared to 
the first-generation platform by more than 100%. An electrical stimulation regimen was 
developed that improved both tissue force output and calcium handling properties. When 
modeling the 403Q mutation associated with hypertrophic cardiomyopathy, under standard 
culture the mutated tissues produced higher contractile force than the WT tissues. Under 
the presence of ascorbic acid, the mutated tissues produced lower contractile force than the 
WT tissues. Immunofluorescent imaging showed an increase in collagen deposition in the 
mutated tissues treated with ascorbic acid compared to WT tissues. These findings suggest 
that this micro-device platform can be potentially used for both mechanistic and drug 
discovery studies.  
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